BKI1_ARATH
ID BKI1_ARATH Reviewed; 337 AA.
AC Q9FMZ0; Q8LBG8;
DT 28-JUN-2011, integrated into UniProtKB/Swiss-Prot.
DT 01-MAR-2001, sequence version 1.
DT 25-MAY-2022, entry version 108.
DE RecName: Full=BRI1 kinase inhibitor 1;
GN Name=BKI1; OrderedLocusNames=At5g42750; ORFNames=MJB21.13;
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliopsida; eudicotyledons; Gunneridae; Pentapetalae;
OC rosids; malvids; Brassicales; Brassicaceae; Camelineae; Arabidopsis.
OX NCBI_TaxID=3702;
RN [1]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC STRAIN=cv. Columbia;
RX PubMed=9501997; DOI=10.1093/dnares/4.6.401;
RA Nakamura Y., Sato S., Kaneko T., Kotani H., Asamizu E., Miyajima N.,
RA Tabata S.;
RT "Structural analysis of Arabidopsis thaliana chromosome 5. III. Sequence
RT features of the regions of 1,191,918 bp covered by seventeen physically
RT assigned P1 clones.";
RL DNA Res. 4:401-414(1997).
RN [2]
RP GENOME REANNOTATION.
RC STRAIN=cv. Columbia;
RX PubMed=27862469; DOI=10.1111/tpj.13415;
RA Cheng C.Y., Krishnakumar V., Chan A.P., Thibaud-Nissen F., Schobel S.,
RA Town C.D.;
RT "Araport11: a complete reannotation of the Arabidopsis thaliana reference
RT genome.";
RL Plant J. 89:789-804(2017).
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA Brover V.V., Troukhan M.E., Alexandrov N.A., Lu Y.-P., Flavell R.B.,
RA Feldmann K.A.;
RT "Full-length cDNA from Arabidopsis thaliana.";
RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA De Los Reyes C., Quan R., Chen H., Bautista V., Kim C.J., Ecker J.R.;
RT "Arabidopsis ORF clones.";
RL Submitted (JUN-2008) to the EMBL/GenBank/DDBJ databases.
RN [5]
RP FUNCTION, INTERACTION WITH BRI1, TISSUE SPECIFICITY, AND PHOSPHORYLATION.
RX PubMed=16857903; DOI=10.1126/science.1127593;
RA Wang X., Chory J.;
RT "Brassinosteroids regulate dissociation of BKI1, a negative regulator of
RT BRI1 signaling, from the plasma membrane.";
RL Science 313:1118-1122(2006).
RN [6]
RP SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-211, AND MUTAGENESIS OF
RP 179-ARG-LYS-180; 197-LYS-LYS-198; 209-LYS-LYS-210; TYR-211; 218-LYS-LYS-219
RP AND CYS-322.
RX PubMed=21289069; DOI=10.1101/gad.2001911;
RA Jaillais Y., Hothorn M., Belkhadir Y., Dabi T., Nimchuk Z.L.,
RA Meyerowitz E.M., Chory J.;
RT "Tyrosine phosphorylation controls brassinosteroid receptor activation by
RT triggering membrane release of its kinase inhibitor.";
RL Genes Dev. 25:232-237(2011).
CC -!- FUNCTION: Negative regulator of brassinosteroid signaling. When
CC associated to the membrane, limits the interaction of BRI1 with BAK1 by
CC binding to the kinase-inactive form of BRI1.
CC {ECO:0000269|PubMed:16857903}.
CC -!- SUBUNIT: Interacts (via C-terminus) with BRI1 (via kinase domain).
CC {ECO:0000269|PubMed:16857903}.
CC -!- INTERACTION:
CC Q9FMZ0; Q9ZWC8: BRL1; NbExp=4; IntAct=EBI-1111615, EBI-590903;
CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:21289069}.
CC Cytoplasm {ECO:0000269|PubMed:21289069}. Note=Once phosphorylated
CC following brassinosteroid treatment, displaced from the plasma membrane
CC into the cytosol where it is inactive.
CC -!- TISSUE SPECIFICITY: Expressed in leaves, petioles, shoot apices,
CC hypocotyls, roots and flowers. {ECO:0000269|PubMed:16857903}.
CC -!- DOMAIN: The c-terminal part (253-337) is necessary and sufficient for
CC the interaction with BRI1.
CC -!- PTM: Phosphorylated on Tyr-211 in response to brassinosteroid
CC perception, leading to its inactivation: once phosphorylated, displaced
CC into the cytosol where it is inactive. {ECO:0000269|PubMed:16857903,
CC ECO:0000269|PubMed:21289069}.
CC -!- MISCELLANEOUS: BRI1 is not required for BKI1 association with the
CC plasma membrane, but the BRI1 kinase activity is necessary for the
CC membrane release.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AB007647; BAB10631.1; -; Genomic_DNA.
DR EMBL; CP002688; AED94856.1; -; Genomic_DNA.
DR EMBL; AY087216; AAM64772.1; -; mRNA.
DR EMBL; BT033090; ACF04813.1; -; mRNA.
DR RefSeq; NP_568610.1; NM_123639.3.
DR PDB; 4OH4; X-ray; 2.25 A; E/F=306-325.
DR PDB; 4Q5J; X-ray; 2.77 A; E/F=306-325.
DR PDBsum; 4OH4; -.
DR PDBsum; 4Q5J; -.
DR AlphaFoldDB; Q9FMZ0; -.
DR SMR; Q9FMZ0; -.
DR BioGRID; 19534; 1.
DR IntAct; Q9FMZ0; 1.
DR STRING; 3702.AT5G42750.1; -.
DR iPTMnet; Q9FMZ0; -.
DR PaxDb; Q9FMZ0; -.
DR PRIDE; Q9FMZ0; -.
DR ProteomicsDB; 240353; -.
DR EnsemblPlants; AT5G42750.1; AT5G42750.1; AT5G42750.
DR GeneID; 834284; -.
DR Gramene; AT5G42750.1; AT5G42750.1; AT5G42750.
DR KEGG; ath:AT5G42750; -.
DR Araport; AT5G42750; -.
DR TAIR; locus:2165472; AT5G42750.
DR eggNOG; ENOG502QT0J; Eukaryota.
DR HOGENOM; CLU_869899_0_0_1; -.
DR InParanoid; Q9FMZ0; -.
DR OMA; KYIRMLF; -.
DR OrthoDB; 1319803at2759; -.
DR PhylomeDB; Q9FMZ0; -.
DR PRO; PR:Q9FMZ0; -.
DR Proteomes; UP000006548; Chromosome 5.
DR ExpressionAtlas; Q9FMZ0; baseline and differential.
DR Genevisible; Q9FMZ0; AT.
DR GO; GO:0005829; C:cytosol; IDA:TAIR.
DR GO; GO:0005886; C:plasma membrane; IDA:TAIR.
DR GO; GO:0046982; F:protein heterodimerization activity; IPI:TAIR.
DR GO; GO:0004860; F:protein kinase inhibitor activity; IDA:TAIR.
DR GO; GO:0009742; P:brassinosteroid mediated signaling pathway; IEA:UniProtKB-KW.
DR GO; GO:0006629; P:lipid metabolic process; IEA:UniProtKB-KW.
DR GO; GO:0010423; P:negative regulation of brassinosteroid biosynthetic process; IMP:TAIR.
DR InterPro; IPR039620; BKI1/MAKR1/3/4.
DR PANTHER; PTHR33312; PTHR33312; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Brassinosteroid signaling pathway; Cell membrane; Cytoplasm;
KW Lipid metabolism; Membrane; Phosphoprotein; Reference proteome.
FT CHAIN 1..337
FT /note="BRI1 kinase inhibitor 1"
FT /id="PRO_0000410475"
FT REGION 1..38
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 51..72
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 270..310
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 273..310
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT MOD_RES 211
FT /note="Phosphotyrosine"
FT /evidence="ECO:0000269|PubMed:21289069"
FT MUTAGEN 179..180
FT /note="RK->AA: No effect on subcellular location. Cytosolic
FT only; when associated with 197-A-A-198 or 197-A-A-198 and
FT 209-A-A-210 and 218-A-A-219."
FT /evidence="ECO:0000269|PubMed:21289069"
FT MUTAGEN 197..198
FT /note="KK->AA: Reduced cell membrane localization.
FT Cytosolic only; when associated with 179-A-A-180 or 179-A-
FT A-180 and 209-A-A-210 and 218-A-A-219."
FT /evidence="ECO:0000269|PubMed:21289069"
FT MUTAGEN 209..210
FT /note="KK->AA: Reduced cell membrane localization.
FT Cytosolic only; when associated with 218-A-A-219 or 179-A-
FT A-180 and 197-A-A-198 and 218-A-A-219."
FT /evidence="ECO:0000269|PubMed:21289069"
FT MUTAGEN 211
FT /note="Y->D: Cytosolic. Loss of membrane localization in
FT absence of brassinosteroid treatment."
FT /evidence="ECO:0000269|PubMed:21289069"
FT MUTAGEN 211
FT /note="Y->F: Loss of cytosolic localization. No
FT dissociation from the membrane upon brassinosteroid
FT treatment."
FT /evidence="ECO:0000269|PubMed:21289069"
FT MUTAGEN 218..219
FT /note="KR->AA: No effect on subcellular location. Cytosolic
FT only; when associated with 209-A-A-210 or 179-A-A-180 and
FT 197-A-A-198 and 209-A-A-210."
FT /evidence="ECO:0000269|PubMed:21289069"
FT MUTAGEN 322
FT /note="C->A: No effect on phosphorylation and subcellular
FT location."
FT /evidence="ECO:0000269|PubMed:21289069"
FT HELIX 308..321
FT /evidence="ECO:0007829|PDB:4OH4"
SQ SEQUENCE 337 AA; 37104 MW; 62625FE75B488490 CRC64;
METNLQQVKN SSQTFSEKQN PKQEASPSPI SSTCSSPSHD FSFTISLQPL SSSSKHISPT
LRSPSKTTSS YQQTDPFAVD LSPADEIFFH GHLLPLHLLS HLPVSPRTST GSYNDGFTLP
VKDILPDQPT NNNNNTENAI TNISTEAKDD NTEDKAEGEI RVKTKPIKSF SLFGLSKWRK
GFESNEREQE QQQQKIKKPM SLDLSHAVKK YIRMLFQKRG NGTQFWNRRQ TSSYSFSSSL
MGPNGNSKTM INGSYNKRDL IRGRRGELFS APASMRTSPT NSGHLRVSTA GLSSSSGSTS
SSSSDSTMEE LQAAIQAAIA HCKNSSAVDR DDKVKDS
